I think it will reach +2 when it releases its news about the 401 products. They keep moving back the confrence to try to talk about the product.
Cool. We'll keep an eye on it.
seems reasonable entry price too... i would say that has a lot of potential for a nice stead boom.... ill for sure also keep an eye on it... chahine
I think it will drop to maybe the high 90's and that is an excellent entry point because its not going to go lower. All i can say is get in before confrence call which should be around en of march :)
we'll watch it and see..
wow...some boom, wont go below the high 90's eh? lol, whatever, but do u still think this has potential now that that conference or w/e didnt do much...?
Well I wish I'd seen your original post back in January (wasn't a member then though) as ISV climbed up to 1.20. ISV has since fell back to its current 0.67 and EYET which priced at 21, opened strong at 30, is now trading at 45. Both had interesting stories. Personally I find it really hard to invest in stocks that don't have earnings. I'd have to trade them on their technicals. I wonder if they both have good stories now.
Stocks without earnings don't usually do much.
thank you captain obvious
That is not obvious to a lot of people. I don't think the average investor even knows what earnings are or how they relate to what a company does. A lot of people think a "stock" is just a certificate, and they don't look at the company behind it. And plenty of bagholders buy companies with not only no earnings, but no chance of earnings.
You've got to have that speculative nature. Many stocks with negative earnings are growth stocks. Companies that are putting all the resources they can come up with into growing their Sales. You have to have confidence that they will deliver earnings in the future and their stock price will be attached to that expected future earnings. The stock price is also more volatile because of the uncertainty of future earnings. Another type of stock that often is losing money and trades on expected future sales are biotechs. They have drugs they are designing and trying to bring to market. When a clinical trial goes bad or good it is immediately priced into its expected future earnings and current stock price. It's this total uncertainty of earnings I don't like.
True. A great example is Sirius, which we talk about on here frequently. The potential is huge. But for now Sirius is burning cash and no one can make a realistic guess on when they may have earnings. It's tough to price a stock like that.
Copyright 2008, All Rights Reserved. Thanks for visiting a Performance Marketing Group Network Website. Advertise Here. Please visit one of our other quality websites.: